PMID- 32695659
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 10
DP  - 2020
TI  - Myb Immunohistochemical Staining and Fluorescence in situ Hybridization in 
      Salivary Rare Basaloid Lesions.
PG  - 870
LID - 10.3389/fonc.2020.00870 [doi]
LID - 870
AB  - Objective: Salivary rare basaloid lesions, including cribriform type basal cell 
      adenoma (cBCA), BCA with incomplete capsule (iBCA), sialoblastoma (SB), and 
      intercalated duct hyperplasia (IDH), could easily be misdiagnosed as adenoid 
      cystic carcinoma (AdCC). We aim to identify an approach for differential 
      diagnosis and to establish an optimal workflow concerning the diagnosis of these 
      lesions. Material and methods: A panel of antibodies (MYB, beta-catenin, CD117, 
      SOX10, ki67, P63, calponin) and fluorescence in situ hybridization (FISH)-MYB 
      were utilized to distinguish above salivary basaloid diseases from AdCC. Results: 
      Histologically, the striking diagnostic features of cBCA, iBCA, SB, and IDH are 
      composed of basaloid tumor cells, well-defined encapsulation, or lack of 
      destructive invasion. Immunohistochemically, Myb immune-labeling could 
      effectively make a distinction among cBCA, iBCA, SB, and IDH from AdCC, except in 
      SB. cBCA and iBCA typically expressed beta-catenin in the nuclei of tumor cells. 
      There was no statistical significance in the ki67 index between SB and AdCC, but 
      their indices were significantly higher than those of iBCA and IDH (p < 0.05, p < 
      0.05, respectively). P63 and calponin immune-expression were observed in the 
      basaloid or myoepithelial cells. CD117 were observed positively in cBCA, iBCA, 
      SB, and AdCC, except in IDH. SOX10 were observed positively in all cases. No 
      cases had fusion of MYB and NFIB detectable by FISH, except in AdCC. Conclusion: 
      Considering their sensitivity and specificity, FISH-Myb and an 
      immunohistochemical panel of MYB/beta-catenin/ki67 would be an optimal choice for 
      the differential diagnosis of these basaloid lesions. Clinical relevance: Some 
      salivary basaloid tumor or tumor-like lesions have overlapping features with 
      AdCC. Through this present research, we suggested that the panel IHC of MYB, 
      betacatenin, and ki67 combined with FISH-Myb should be an optimal choice for 
      differential diagnosis among those lesions.
CI  - Copyright (c) 2020 Li, Jie and He.
FAU - Li, Binbin
AU  - Li B
AD  - Department of Oral Pathology, Peking University School and Hospital of 
      Stomatology, Beijing, China.
AD  - Research Unit of Precision Pathologic Diagnosis in Tumors of the Oral and 
      Maxillofacial Regions, Chinese Academy of Medical Sciences, Beijing, China.
AD  - National Clinical Research Center for Oral Diseases, Peking University School and 
      Hospital of Stomatology, Beijing, China.
FAU - Jie, Weiping
AU  - Jie W
AD  - Department of Oral Pathology, Peking University School and Hospital of 
      Stomatology, Beijing, China.
AD  - Research Unit of Precision Pathologic Diagnosis in Tumors of the Oral and 
      Maxillofacial Regions, Chinese Academy of Medical Sciences, Beijing, China.
AD  - National Clinical Research Center for Oral Diseases, Peking University School and 
      Hospital of Stomatology, Beijing, China.
FAU - He, Huiying
AU  - He H
AD  - Department of Pathology, School of Basic Medical Sciences, Third Hospital, Peking 
      University Health Science Center, Beijing, China.
LA  - eng
PT  - Journal Article
DEP - 20200630
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC7339910
OTO - NOTNLM
OT  - MYB
OT  - adenoid cystic carcinoma
OT  - fluorescence in situ hybridization
OT  - immunohistochemistry
OT  - salivary basaloid lesions
EDAT- 2020/07/23 06:00
MHDA- 2020/07/23 06:01
PMCR- 2020/01/01
CRDT- 2020/07/23 06:00
PHST- 2019/09/15 00:00 [received]
PHST- 2020/05/04 00:00 [accepted]
PHST- 2020/07/23 06:00 [entrez]
PHST- 2020/07/23 06:00 [pubmed]
PHST- 2020/07/23 06:01 [medline]
PHST- 2020/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2020.00870 [doi]
PST - epublish
SO  - Front Oncol. 2020 Jun 30;10:870. doi: 10.3389/fonc.2020.00870. eCollection 2020.